Find out how a team of scientists improved their throughput and reproducibility using Bio-Techne’s automated ELISA platform.

We teamed up with Uwe Wessels to show the capability of Ella, our automated ELISA instrument. Uwe Wessels is a scientist at the Roche Innovation Center in Munich, where he is responsible for the development and quantification of bioanalytical assays for novel therapeutics. He has over 17 years of experience using multiple bioanalytical platforms including ELISAs, Luminex®, and Ella.


Speaker:

Uwe Wessels
Uwe Wessels
pRED Pharmaceutical Sciences, Bioanalytical R&D,
Roche Innovation Center Munich

Uwe Wessels works alongside Kay Stubenrauch and Klaus Mackeben, focusing mainly on assay development that is highly specific and sensitive for pharmacokinetics (PK), anti-drug antibodies (ADA) and pharmacodynamics (PD) analysis. The assays they develop are used by different CROs all over the world, so successful assay transfer is key. They transferred two of their heavily used ELISA based PK1 and ADA2 assays onto the Ella platform.

Why Ella?

Ella’s combination of superior performance, throughput and data quality takes immunoassays to the next level. In just 90 minutes, researchers can achieve highly reproducible assay data with little manual steps using 2.5 - 25 µL of their sample.

Ella can be used to streamline not only drug quantification, but bioprocess development, and immunology, cancer and neuroscience research –to name a few key areas.

Listen to this webinar and you’ll find out how Uwe and his colleagues increased their assay speed by 3x using Ella!

1 Stubenrauch K, Wessels U, Essig U, Kowalesky F, Vogel R, Heinrich J: J Pharm Biomed Anal. 72 (2013) 208-215
2 Stubenrauch K, Wessels U, Essig U, Vogel R, Schleypen J: J Pharm Biomed Anal. 52 (2010) 249-254